Brief: EMA Recommends Restricting Use Of Cancer Medicine Rubraca
22/07/2022 11:59
July 22 (Reuters) - European Medicines Agency:
* EMA: EMA RECOMMENDS RESTRICTING USE OF CANCER MEDICINE
RUBRACA:
22/07/2022
* EMA - RECOMMENDATION DOES NOT AFFECT USE OF RUBRACA AS
MAINTENANCE TREATMENT FOLLOWING CHEMOTHERAPY
Source text for Eikon: ID:
Further company coverage: CLVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clovis Oncology
See all newsBrief: Clovis Oncology Inc - On April 5, 2023, Entered Into Asset Purchase Agreement With Pharma& To Sell Product Business For Upfront Payment Of $70 Million
Brief: Clovis Oncology Enters Into Financing Agreement
Brief: Clovis Oncology Inc Received Written Notice From Nasdaq That Company's Common Stock Will Be Delisted From Nasdaq
U.S. STOCKS ON THE MOVE-Nike, Faraday Future, PBF Energy
U.S. STOCKS ON THE MOVE-Natural gas, Box Inc, Weber